References
- Azizi M., Guyene T. T., Chatellier G., Menard J. Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension. Journal of Hypertension 1994; 12: 419–127
- Edwards C. R. W., Padfield P. L. Angiotensin-converting enzyme inhibitors: past, present and bright future. Lancet 1985; 1: 30–34
- Fischli W., Clozel J-P., El Amrani K., Wostl W., Neidhart W., Stadler H., Branca Q. Ro 42–5892 is a potent orally active renin inhibitor in primates. Hypertension 1991; 18: 22–31
- Kiowski W., Beerman J., Rickenbacher P., Haemmerli R., Thomas M., Burkart F., Meinertz T. Comparison of acute hemodynamic effects of renin and angiotensin converting enzyme inhibition in patients with chronic heart failure. Circulation 1994; 90: 2748–2756
- Kleinbloesem C. H., Weber C., Fahrner E., Dellenbach M., Welker H., Schröter V., Belz G. G. Hemodynamics, biochemical effects and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects. Clinical Pharmacology and Therapeutics 1993; 53: 585–592
- Kobrin I., Viskoper R. J., Laszt A., Bock J., Weber C., Charlon V. Effects of an orally active renin inhibitor, Ro 42–5892, in patients with essential hypertension. American Journal of Hypertension 1993; 6: 349–356
- Kokubu T., Hiwada K. Human renin inhibitors. Drugs Today 1987; 23: 101–108
- Lindgren B. R., Andersson R. G. G. Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough. Medical Toxicology and Adverse Drug Experimentation 1989; 4: 369–380
- Lowry O. H., Rosebrough N. J., Farr L., Randall R. J. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 1951; 193: 265–275
- Omura T., Sato R. The carbon monoxide binding pigment of liver microsomes. Journal of Biological Chemistry 1964; 239: 2370–2385
- Van Den Meiracker A. H., Admiraal P. J. J., Man In 't Veld A. J., Derkx F. H. M., Ritsema van Eck H. J., Mulder P., van Brummelen P., Schalekamp M. A. D.H. Prolonged blood pressure reduction by orally active renin inhibitor Ro 42–5892 in essential hypertension. British Medical Journal 1990; 301: 205–210
- Viskoper R. J., Charlon V., Laszt A., Yosefy C., Bock J., Landau M., Kobrin I. Time dependency of the antihypertensive efficacy of the new renin inhibitor Ro 42–5892. Journal of Human Hypertension 1994; 8: 133–136
- Waeber B., Nussberger J., Brunner H. R. The renin-angiotensin system: role in experimental and human hypertension. Handbook of Hypertension, W. H. Birkenhaeger, J. L. Reid. Elsevier, Amsterdam 1986; 489–519, 8